A result needs a clinical question

A genomic report can look like an unusually detailed map of a cancer. It may name genes, pathways, medicines and trials, sometimes across many pages. Detail can create the impression that a precise answer must be hidden somewhere in the document. Yet the most important question comes before the result: which decision is the test intended to inform? Without that question, a long list of findings can be mistaken for a long list of effective options. The task is to connect information with an action supported for this person’s situation.

I approach this subject by separating measurement, interpretation and decision. The laboratory measures something in a sample. Clinicians interpret its significance alongside the pathology and history. A treatment decision then considers evidence, potential benefit, risks, eligibility and the person’s priorities. Those stages are connected, but they are not interchangeable. A molecular finding can be accurate without being useful for a current treatment choice. Understanding that possibility helps make a report less mysterious and a consultation more productive.

Evidence: biomarkers include more than DNA

NCI describes cancer biomarkers as genes, proteins and other substances that provide information about a tumour. Testing may help select a targeted therapy or immunotherapy, identify an unsuitable treatment, or locate a relevant trial. The material can come from tumour tissue or, for certain tests, a blood sample. Some reports identify no useful treatment match; others contain benign changes or variants whose effects are not known. A finding labelled uncertain is not a direction to try a medicine or supplement. [1]

The broader tumour-marker category also includes measurements used in diagnosis, prognosis, response assessment or recurrence monitoring. A raised marker does not necessarily mean cancer is present, because benign conditions can affect some markers and some cancers do not raise the expected marker. Results generally need other clinical information. Many circulating markers are unsuitable for general screening because they do not reliably distinguish everyone with cancer from everyone without it. [2] A marker useful during treatment should therefore not be casually repurposed as a wellness screening test.

Evidence: predictive and prognostic answer different questions

NCI’s diagnostic research framework distinguishes diagnostic markers, which help identify a cancer’s origin or subtype; prognostic markers, which inform the likelihood of an outcome; and predictive markers, which inform response to a particular therapy. [3] These words are easy to confuse because all appear to describe the future. Their clinical roles differ. A marker associated with recurrence risk does not automatically identify the treatment that will reduce that risk. A marker that predicts benefit from a drug may say little about other aspects of the illness.

This vocabulary is useful in an appointment. If a report calls a feature unfavourable, ask what kind of information it supplies. Does it change staging, treatment selection, follow-up, or simply the discussion of uncertainty? If a treatment is described as matched, ask what evidence links that exact finding to benefit in this disease setting. A connection demonstrated in one setting may require further study in another. Precision in language makes room for hope while limiting the tendency to turn a promising biological association into a guarantee.

Evidence: a companion diagnostic has a defined job

The FDA describes a companion diagnostic as a test providing information essential to the safe and effective use of a corresponding therapeutic product. Its role can include identifying people more likely to benefit, those at particular risk of serious adverse effects, or information needed to monitor a treatment. Inaccurate testing can lead to an inappropriate decision. [4] This is a relationship between a particular test, an intended use and a therapy, rather than an endorsement of any test that measures something with a similar name.

For patients, the implication is to keep the test report attached to the treatment discussion. The method, sample, indication and interpretation matter. It is reasonable to ask whether the proposed test is the one required for the therapy under consideration and whether the result is sufficient for that decision. A commercial advertisement may describe the breadth of a panel; a clinician needs to establish its relevance. The number of features measured is not, by itself, evidence that the panel will improve a person’s outcome.

Evidence: tumour testing and inherited-risk testing are different

Somatic tumour changes arise during life; germline changes are present outside the tumour and may be inherited. NCI distinguishes testing intended to guide cancer treatment from testing for inherited susceptibility. Tumour testing sometimes raises a possible inherited finding, but it does not replace a dedicated inherited-risk assessment. Genetic counselling can help explain what a result could mean for the individual and relatives before further testing is considered. Family history remains relevant even when the immediate question is treatment selection. [5]

The NCI cancer genetics overview adds an important boundary: the absence of a finding in tumour testing does not rule out inherited susceptibility when the personal or family history is suggestive. Conversely, a suspected inherited finding from tumour sequencing may need confirmation through appropriate germline testing. [6] A family should not be asked to reorganise its medical care around an unconfirmed interpretation of a tumour report. Establish what has actually been tested, what remains uncertain, and which professional will coordinate any next step.

Practical implications: prepare for the report discussion

Ask the team to identify the main finding in plain language and state what it changes today. A useful explanation might distinguish a standard treatment option, a possible trial, a finding that predicts resistance, and a result that currently has no action attached. These categories should not be blended into a single list of possibilities. Request the actual report for your records and ask who will interpret it if care moves to another centre. The report’s meaning should travel with it, not just its gene names.

Timing also deserves discussion. Ask when results are expected, whether a current treatment decision depends on them, and what the plan is if material is inadequate or a result is delayed. This does not mean postponing prescribed care while seeking an ever larger panel. It means understanding the sequence your team recommends. Financial coverage and access can be discussed openly as part of that sequence. A test that cannot be completed in time, or an option that is not accessible, creates practical questions that deserve attention rather than embarrassment.

Practical implications: resist the leap from mechanism to remedy

A pathway named in a report may also appear in advertisements for dietary supplements or experimental interventions. Shared terminology is not sufficient evidence that a product can treat the cancer. To make that connection, one would need reliable clinical evidence for the intervention, the relevant disease setting and an acceptable safety profile, not merely a cell-culture mechanism. Bring proposed supplements to the oncology pharmacist or treatment team. A book, ingredient list or biological analogy cannot substitute for a treatment decision made with the full clinical record.

In my Nicolaev Medicine author framework, context means keeping different levels of explanation visible. Molecular events, a person’s lived experience, treatment burden and practical support can all deserve attention. That does not make the framework a method for decoding a variant or overriding a pathology result. Energy, frequency or coherence language should not be presented as established oncology treatment. The useful contribution of a broader perspective is to ask clearer questions about care, not to claim authority over decisions for which it has not been clinically validated.

Practical implications: ask how the information will be used

Before testing, ask what the consent process covers. Who will receive the clinical result, and is research use of the sample or data a separate choice? If a possible inherited finding appears, how will it be communicated and who will help explain it? These questions do not imply that testing should be avoided. They help a person understand the scope of the decision being made, especially when a test has both a treatment purpose and the possibility of information relevant to relatives.

After testing, ask the clinician to separate what is established from what may change with future research. Keep that distinction in your own notes. If a report is later reinterpreted, clarify whether the new interpretation changes the current plan or simply updates the record. A manageable summary can sit alongside the full document: the purpose of testing, the finding that matters now, the decision agreed, and who is responsible for the next step. Good records support continuity without asking patients to become molecular pathologists.

Limits and unanswered questions: information is not certainty

Genomic profiling cannot promise that every tumour will reveal an actionable target or that a matched treatment will succeed. Research is improving how findings are interpreted, but an individual report still needs a discussion of uncertainty. Ask what would count as a meaningful benefit, how response will be assessed, and what would prompt reconsideration. A result without an immediate option is not proof that testing was pointless, but neither should its future possibilities be sold as present clinical benefit. The distinction matters when choices are urgent or costly.

The aim is informed participation rather than independent interpretation of a highly technical report. Keep a small set of questions visible: what was measured, what does it mean, how strong is the evidence, what decision follows, and what happens if the result does not answer the question? These questions also reveal when a second specialist explanation could be helpful. Personalised care is not defined by the length of the report. It is defined by how responsibly the available information is brought into decisions with the person who must live with them.

Related reading

Author and medical note

Written by . This is general educational writing and author analysis, not a personal diagnosis or treatment plan. Discuss symptoms, treatment changes and supplement interactions with a qualified clinician. No independent medical review is claimed.

References

  1. National Cancer Institute. Biomarker Testing for Cancer Treatment.
  2. National Cancer Institute. Tumor Markers.
  3. National Cancer Institute. Diagnostics Research and Development Resources: What Makes a Marker Useful.
  4. US Food and Drug Administration. Companion Diagnostics.
  5. National Cancer Institute. Genetic Testing for Inherited Cancer Risk.
  6. National Cancer Institute. Cancer Genetics Overview (PDQ®)–Health Professional Version.

Gabriel Nicolaev – CyGuru